



Pharmaron Beijing Co., Ltd.

8th Floor, Block 1

6 Tai-He Road

Beijing Economic Technological Development Zone

Beijing, China

Pharmaron Beijing Co., Ltd (the “Issuer”)

USD 300 Million Zero Coupon Convertible Bonds due 2026

(ISIN: XS2352395748) (the “USD Bonds”) and

RMB 1,916 Million USD Settled Zero Coupon Convertible Bonds due 2026

(ISIN: XS2353011724) (the “RMB Bonds”)

(together, the “Bonds”)

Notice to Bondholders

Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the terms and conditions of the Bonds (the “Conditions”).

The Issuer hereby gives notice that, as approved by the shareholders' meeting dated 21 June 2023 of a final dividend (the **“Final Dividend”**) comprising of (i) a cash dividend of RMB 3.0 (inclusive of tax) per 10 Ordinary Shares and (ii) 5 new Ordinary Shares for every 10 existing Ordinary Shares to be issued out of reserve to all Shareholders, pursuant to Condition 5.3.2(i) and Condition 5.3.3 of the Conditions, effective 27 July 2023 the Conversion Prices of each of the Bonds have been adjusted as follows:

- to HKD 110.32 for the USD Bonds (from previously HKD 166.42)
- to HKD 100.97 for the RMB Bonds (from previously HKD 152.32)

Any Bondholder who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

PHARMARON BEIJING CO., LTD.

(康龍化成 (北京) 新藥技術股份有限公司)

Name: LI Shing Chung Gilbert
Title: Chief Financial Officer

26 July 2023